We are live on
!
Find out more
ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
55 hedge funds and large institutions have $5.47M invested in Adaptimmune Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
80% less capital invested
Capital invested by funds: $27.7M → $5.47M (-$22.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
55
Holding in Top 10
–
Calls
$37K
Puts
$27K
Top Buyers
| 1 | +$906K | |
| 2 | +$385K | |
| 3 | +$298K | |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$68.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.5K |
Top Sellers
| 1 | -$6.57M | |
| 2 | -$5.41M | |
| 3 | -$4.09M | |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$1.15M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.06M |